Amgen’s Biosimilar Trend Report finds that biosimilars have been introduced at a price that is generally 15% to 37% lower than the reference product.
Competition created by biosimilars has saved the U.S. health care system $9.8 billion over the past five years, according to a Amgen’s Biosimilar Trends Report. Biosimilars are launching at a price that is generally 15% to 37% lower than the reference product, and uptake of biosimilars is increasing, the report finds.
Jennifer Norton
“The increasing availability and adoption of biosimilars means these treatments are delivering on the fundamental promise of reducing health care costs for payers, employers, and patients in the United States,” Jennifer Norton, vice president, head of U.S. value and access at Amgen, said in a statement.
Biosimilars for oncology therapeutics have seen strong growth. The five biosimilars of Herceptin (trastuzumab) and two biosimilars of Avastin (bevacizumab) account for nearly 70% of sales by volume. While the prices of all trastuzumab products have declined over time, biosimilar prices are now 24% to 45% lower than the reference product Herceptin’s average sales price. Two years after the first launch, the price of bevacizumab biosimilars is now 22% to 29% lower than the price of reference product Avastin.
The three biosimilars of Rituxan (rituximab) account for 55% of sales by volume. In less than two years after the first launch, the price of rituximab biosimilars is now 15% to 32% lower than the price of reference product.
In oncology supportive care, there are four biosimilars of Neulasta (pegfilgrastim). All four launched between a 33% to 37% discount to the reference product’s wholesale average cost. The two biosimilars to Neupogen (filgrastim), plus Granix (which was approved under a BLA before the biosimilar pathway was established, are now 56% to 64% lower than the reference product.
Other key takeaways from the report include:
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
Using the 'Pathway' Approach to Shorten the Time Between Cancer Diagnosis and Treatment
November 16th 2022In this episode of Tuning In to the C-Suite, Briana Contreras, editor with Managed Healthcare Executive spoke with Dr. Yuri Fesko, oncologist and vice president of Medical Affairs at Quest Diagnostics. In the conversation, Dr. Fesko addressed the ongoing issue of long gaps of times between receiving a diagnosis for a type of cancer and finally getting the treatment for it. Dr. Fesko shared the benefits a number of sectors receive when treating patients sooner and the steps to get there.
Listen
Microplastics, Diet and More: What’s Causing Early-Onset Cancer?
March 18th 2025In a February 2025 Time magazine cover story, Jamie Ducharme reports on this atypical and disquieting trend. Ducharme cites a 79% increase in early-onset cancer diagnoses and a 28% increase in cancer-related deaths in this age group from 1990 to 2019.
Read More